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Intranasal administration of oxytocin (OXT) might be a promising new adjunctive therapy for mental disorders characterized by social
behavioral alterations such as autism and schizophrenia. Despite promising initial studies in humans, it is not yet clear the specificity of the
behavioral effects induced by chronic intranasal OXT and if chronic intranasal OXT could have different effects compared with single
administration. This is critical for the aforementioned chronic mental disorders that might potentially involve life-long treatments. As a first
step to address these issues, here we report that chronic intranasal OXT treatment in wild-type C57BL/6J adult mice produced a
selective reduction of social behaviors concomitant to a reduction of the OXT receptors throughout the brain. Conversely, acute
intranasal OXT treatment produced partial increases in social behaviors towards opposite-sex novel-stimulus female mice, while on the
other hand, it decreased social exploration of same-sex novel stimulus male mice, without affecting social behavior towards familiar
stimulus male mice. Finally, prolonged exposure to intranasal OXT treatments did not alter, in wild-type animals, parameters of general
health such as body weight, locomotor activity, olfactory and auditory functions, nor parameters of memory and sensorimotor gating
abilities. These results indicate that a prolonged over-stimulation of a ‘healthy’ oxytocinergic brain system, with no inherent deficits in
social interaction and normal endogenous levels of OXT, results in specific detrimental effects in social behaviors.
Neuropsychopharmacology (2014) 39, 1102–1114; doi:10.1038/npp.2013.310; published online 4 December 2013
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INTRODUCTION
The neuropeptide oxytocin (OXT) has been strongly
implicated in social behaviors including social recognition,
social approach, pair bonding, paternal care and maternal
behavior (Lim et al, 2005; Sala et al, 2011; Winslow and
Insel, 2002). This has led to the proposal of its use as an
adjunctive therapeutic treatment in neuropsychiatric dis-
eases characterized by impaired social behaviors, such as
social anxiety disorder, borderline personality disorder,
autism spectrum disorders and schizophrenia (Meyer-
Lindenberg et al, 2011; Striepens et al, 2011). This would
be particularly important as social alterations are consid-
ered among the most debilitating core features of these
mental illnesses, and currently available treatments are not
effective in ameliorating these symptoms.
Intranasal administration of neuropeptides holds promis-
ing potential for the treatment of brain diseases as it might
deliver biologically effective concentrations to the brain
without eliciting potent systemic hormone-like side effects
(Born et al, 2002). Intranasal administration of vasopressin
(AVP) and of OXT have been reported, in rats and mice, to
increase the intracerebral concentration of these peptides,
not only in the cerebrospinal fluid but also in selected brain
regions (Born et al, 2002; Neumann et al, 2013). However,
central effects might be also due to AVP/OXT endogenous
release mediated by peripheral mechanisms (Ludwig et al,
2013). Whatever the mechanism(s) involved, there is no
doubt that central effects are observed in humans after
intranasal administration (Veening and Olivier, 2013).
Acute intranasal OXT seems to produce no negative side
effects in both healthy volunteers and subjects with
developmental or mental health difficulties when delivered
in doses of 18–40 IU (MacDonald et al, 2011). Moreover, in
subjects diagnosed with autism, a single intranasal admin-
istration of OXT might be able to improve, at least
temporarily, emotion recognition abilities in the Reading
the Mind in the Eyes test and the patients’ ability to process
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socially relevant cues in a computer-based game (Andari
et al, 2010; Green and Hollander, 2010; Guastella et al,
2010). Furthermore, in patients with schizophrenia, an
adjunctive 3-week treatment with intranasal OXT has been
found to significantly improve Positive and Negative
Syndrome Scale (PANSS) total scores (Feifel et al, 2010)
and verbal memory measures of the California Verbal
Learning Test (Feifel et al, 2012a).
Despite these promising initial results, it is not yet clear if
chronic intranasal OXT might affect psychiatric-relevant
behavioral measures (eg, in social and memory domains),
and if chronic intranasal OXT has different effects
compared with single administration. This is critical for
the aforementioned chronic mental disorders that might
potentially involve life-long treatments. Unfortunately,
ethical issues, genetic, environmental and clinical hetero-
geneity in human studies might dampen the resolution of
these questions and thus, slow down the progress towards
this new promising therapeutic treatment. In this context,
preclinical studies in rodents might be critical to dissect
OXT-dependent behavioral effects and hold the potential to
better understand the impact of intranasal OXT in brain
functioning. Finally, the possibility to test intranasal OXT
treatments in mice could pave the way for large genetic and
pharmacological screenings aiming to develop more selec-
tive and personalized therapeutic strategies for human
pathologies, such as autism and schizophrenia.
The role of the OXT system has been investigated in
rodent models, but uniquely using OXT-related mutant
mice and giving OXT through intracerebroventricular
(ICV), intraperitoneal (IP) and subcutaneous (SC) injec-
tions (Bielsky and Young, 2004; Jin et al, 2007; Popik et al,
1996; Sala et al, 2012; Sala et al, 2011; Takayanagi et al, 2005;
Winslow and Insel, 2002). Only one recent study in prairie
voles has initiated to investigate the behavioral effects of
intranasal OXT administration before adulthood (ie, from
weaning through sexual maturity; (Bales et al, 2012)). Thus,
the present study is aimed to elucidate the behavioral effects
of intranasal administration of OXT in adult mice. In order
to set the ground for future studies with genetically
modified mice, disease-related mouse models and facilitate
inter-laboratory comparisons, we tested C57BL/6J mice.
This strain of mice is classically used as the background
strain for genetically modified mice and animal models of
neurodegenerative and neurodevelopmental disorders. In
line with clinical settings where intranasal OXT treatments
would be mainly administered to address chronic symp-
toms in psychiatric disorders, we first performed behavioral
and molecular studies in mice undergoing chronic intrana-
sal treatment. Thereafter, we separately tested the effects of
acute intranasal OXT treatment.
MATERIALS AND METHODS
Subjects
All procedures were approved by the Italian Ministry of
Health (permit n. 230/2009-B) and strictly adhere to the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health.
C57BL/6J male mice between 12 and 20 weeks of age used in
this study were obtained from Charles River Laboratories
(France). Animals were housed two to four per cage, in a
climate-controlled animal facility (22 1C±2 1C) and main-
tained on a 12-hour light/dark cycle, with food and water
available ad libitum throughout the experiments. All
behavioral testing and procedures were conducted during
the light phase of the cycle. The experimenter handled the
mice on alternate days during the week preceding the first
behavioral test. Experimenters were blind to the mouse
treatments during testing and behavioral scoring.
Intranasal OXT Administration
OXT (Novartis Pharma AG, Switzerland) was dissolved in
saline (0.9% NaCl) and administered intranasally in a
volume of 5 ml to each mouse in doses of 0.15 IU/5 ml (OXT
0.15 IU) or 0.3 IU/5 ml (OXT 0.3 IU). An amount of 1 IU of
our solution contained 1.667 mg of synthetic OXT. Thus,
0.15 and 0.3 IU corresponded to 0.25005 mg (E2.48e-10 mol)
and 0.5001 mg (E4.96e-10 mol) of OXT, respectively, for each
administration of 5 ml (ie OXT 0.15 IUE9.6 mg/kg or 5 IU/
kg; OXT 0.3 IUE19 mg/kg or 11 IU/kg). These doses were
chosen in order to be much lower than subcutaneous OXT
doses (ie 250 mg/kg) used in mice that could have produced
peripheral effects (Sala et al, 2011). The doses we used are
also similar to the higher range of intranasal OXT doses
recently given to adolescent prairie voles (Bales et al, 2012);
even though in the previous study they used a much higher
volume of injection (ie 25 ml) compared with our study (ie,
5 ml). Control mice received the same volume of saline
(VEH). A 200-ml Eppendorf pipette with gel-loading tips
(Costar) were used for administration. Drops of the 5 ml
solution were gently placed equally on both nostrils of each
mouse, which were taken in when they reflexively inhaled.
Administration was rapid (less than 30 s) and handling was
consistent across treatment groups. The detailed timelines
of each procedural manipulation and OXT treatments are
reported in Supplementary Figure 1. Briefly, for the chronic
intranasal treatments, mice were administered two times a
day, once in the morning and once in the evening, for 7–21
consecutive days and tested as described below, 1 hour after
the last administration. The time of testing was based on
preliminary pilot studies showing that chronic intranasal
OXT treatments of 7, 15 and 21 days produced the same
decrease in social interactions (data not shown). For the
acute intranasal treatments, mice were administered with
OXT only once, 5 min before the test. The delay of only
5 min was chosen based on evidence indicating that
intranasal administration of OXT has very rapid pharma-
cokinetics with effects expected to appear already within a
few minutes (Veening and Olivier, 2013).
Behavioral Testing
Body weight and gross physical appearance. Body
weights and general appearance of the mice were recorded
before each VEH or OXT administration.
Male–female social interaction test. The test was con-
ducted in 2150E Tecniplast cages (35.5 23.5 19 cm)
lightly illuminated (5±1 lux) and video-recorded using a
Unibrain Fire-i digital camera. The video camera was
mounted facing the front of the cage to record the session
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for subsequent scoring of social investigation parameters as
previously described (Scattoni et al, 2011). Unfamiliar
female stimulus mice in estrus were matched to the subject
male mice by age and maintained in social groups of four
per home cage. In a subgroup of animals, ultrasonic
vocalizations (USVs) were also recorded during the test.
See Supplementary Materials and Methods for a detailed
description.
Male–male cagemate social interaction test. A day after
the male–female interaction test, each cage of male mice was
placed in a grey, opaque open-field box (40 40 40 cm)
evenly illuminated with overhead red lighting (5±1 lux) in
the room. Interactions between cagemates were recorded
using an infrared thermal camera (FLIR A315, FLIR
Systems) mounted 1.5 m above the arena for 1 hour. Social
interaction was scored by an automatic videosystem as
previously described (Giancardo et al, 2013).
Olfactory abilities. Mice were individually tested for time
spent sniffing sequential presentations of different odors:
water, two nonsocial odors (ie almond extract and vanilla
extract, Belbake 1 : 20 dilution), and two social odors as
similarly reported previously (Papaleo et al, 2012). The test
was performed on a separate cohort of naı¨ve mice at the
same time-point at which the social interaction test would
have been performed to verify their olfactory abilities after
chronic intranasal OXT administration.
Locomotor activity and temporal order object recognition
(TOR) test. Mice were tested in an experimental apparatus
consisting of an opaque open-field box (40 40 40 cm)
with even, overhead red-light illumination as mentioned
above. Each session was video-recorded using an overhead
camera from ANY-maze (Stoelting). Each mouse was
monitored for its locomotor activity in the empty open-
field boxes for 1 hour. The next day, in the TOR test, the
subjects’ ability to differentiate between two objects
presented at different intervals was assessed as previously
described (Barker et al, 2007). See Supplementary Materials
and Methods for more details.
Acoustic startle response and prepulse inhibition (PPI).
Mice were tested in Startle Response/PPI test system
chambers (TSE Systems GmbH, Germany) using standard
methods as previously described (Papaleo et al, 2008;
Papaleo et al, 2012). In short, a sudden acoustic stimulus
elicits the startle response, while an acoustic, non-startling
prepulse preceding the startle stimulus inhibits the startle
response (PPI). The startle response elicited by sudden
sensory stimuli and its PPI are among some of the most
widely studied phenotypes that are highly conserved across
mammalian species.
Habituation/dishabituation social interaction test. Na-
ı¨ve mice were tested as similarly reported previously
(Ferguson et al, 2000; Scearce-Levie et al, 2008) in 2150E
Tecniplast cages (35.5 23.5 19 cm) lightly illuminated
(5±1 lux) and video-recorded using a Unibrain Fire-i
digital camera. Male mice were individually placed in the
testing cage 1 h prior to the testing. No previous single-
housing manipulation was adopted to avoid any instaura-
tion of home-cage territory and aggressive behaviors.
Testing began 5 min after the intranasal treatment when a
stimulus male mouse was introduced into the testing cage
for a 1-min interaction. At the end of the 1-min trial, we
removed the stimulus animal and returned it to an
individual holding cage. We repeated this sequence for
three trials with 3-min inter-trial intervals introducing the
same stimulus mouse in all three trials. In a fourth
‘dishabituation’ trial, we introduced a new unfamiliar
stimulus mouse in the testing cage. Videos of behaviors
were recorded and subsequently scored offline.
Brain Autoradiography
A separate cohort of naı¨ve mice was handled and
intranasally treated with VEH or OXT as described above
and, at the same time-point when the social interaction test
would have been performed, their brains were rapidly dissected
and frozen in isopentane at  25 1C and then stored
at  80 1C. Brains were cut in coronal sections of 14-mm
thickness and mounted on chrome-alum-gelatin-coated
microscope slides. All slides were stored at  80 1C until
used in receptor autoradiography. The binding procedure
was performed as previously described (Tribollet et al, 1997).
For a detailed description, see Supplementary Materials.
Statistical Analyses
Results are expressed as mean±standard error of the mean
(SEM) throughout. One- or two-way analyses of variance
(ANOVAs) were used for each single parameter measured.
Newman–Keul’s post-hoc test was used for making compar-
isons between groups when the overall ANOVA showed
statistical significant differences for the main factors. The
accepted value for significance was pp0.05. All statistical
analyses were performed using the Statistica version 11
software (Statistica, StatSoft).
RESULTS
Chronic Intranasal OXT Treatment Decreased
Male–Female Social Interaction
The OXT system has been extensively involved in the
modulation of social-related behaviors (Bielsky and Young,
2004; Sala et al, 2012; Sala et al, 2011; Winslow and Insel,
2002). Thus, to assess possible effects of chronic intranasal
OXT treatment in social abilities, we first tested mice
chronically treated with intranasal OXT or VEH in a
classical male–female social interaction test (Scattoni et al,
2011).
A significant OXT-treatment effect was evident for body
sniffing (frequency: F(2,43)¼ 5.69, po0.05; duration: F(2,43)¼
10.14, po0.0005) and anogenital sniffing (frequency:
F(2,43)¼ 4.79, po0.05; duration: F(2,43)¼ 3.86, po0.05). In
particular, compared with the VEH-treated group, male
mice treated with 0.15 or 0.3 IU OXT showed decreased
frequency and duration of body sniffing events (po0.05;
Figure 1a). In addition, for the 0.3-IU OXT group, there was
also a significant decrease in the number of anogenital
sniffing events (po0.05; Figure 1a) and in their duration
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Figure 1 Chronic intranasal OXT treatment decreased male–female social interaction. (a) Frequency of occurrence of various social behaviors such as
head sniffing, body sniffing, angogenital sniffing and following. (b) Duration of events of above-mentioned social behaviors. (c) Frequency of occurrence of
various nonsocial behaviors such as standing/walking alone, digging, grooming, rearing and wall rearing. (d) Duration of events of above-mentioned nonsocial
behaviors. (e) Sum of the frequency of all events of social and nonsocial behaviors. (f) Sum of the duration of all events of social and nonsocial behaviors.
Ns¼ 14 VEH, 16 OXT 0.15 IU/5 ml, 16 OXT 0.3 IU/5 ml. (g) Mean number of USV calls per minute, and (h) mean duration of USVs in milliseconds emitted
by VEH-, OXT 0.15- or OXT 0.3-treated mice. Ns¼ 9 VEH, 16 OXT 0.15 IU/5 ml, 10 OXT 0.3 IU/5 ml. *po0.05, **po0.005, ***po0.0005 vs VEH group.
Values represent mean±SEM throughout all Figures.
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(po0.05; Figure 1b) relative to the VEH group. An effect of
OXT treatment was also observed in nonsocial behaviors
such as standing/walking alone (frequency: F(2,43)¼ 7.68,
po0.005; duration: F(2,43)¼ 5.95, po0.05) and wall rearing
(frequency: F(2,43)¼ 10.98, po0.0005; duration: F(2,43)¼
6.70, po0.005). Specifically, post-hoc tests revealed an
increase in the duration of standing/walking alone (po0.05),
increases in the frequency and duration of wall rearing in
the OXT 0.15-IU group (po0.005), and an increase in the
duration of wall rearing in the OXT 0.3-IU group (p¼ 0.05;
Figure 1c and d).
No significant effect of OXT treatment was observed in
other measures of social interaction such as head sniffing
(frequency: F(2,43)¼ 0.17, p¼ 0.84; duration: F(2,43)¼ 1.11,
p¼ 0.34), following (frequency: F(2,43)¼ 0.47, p¼ 0.63;
duration: F(2,43)¼ 0.36, p¼ 0.70), and mounting (frequency:
F(2,43)¼ 2.41, p¼ 0.14; duration: F(2,43)¼ 2.33, p¼ 0.11;
Figure 1a and b). Similarly, in comparison with the VEH
group, both OXT 0.15 and 0.3 IU groups showed no signi-
ficant differences in nonsocial behaviors such as digging
(frequency: F(2,43)¼ 0.45, p¼ 0.64; duration: F(2,43)¼ 0.27,
p¼ 0.77), grooming (frequency: F(2,43)¼ 0.04, p¼ 0.96;
duration: F(2,43)¼ 1.43, p¼ 0.25) and rearing (frequency:
F(2,43)¼ 0.38, p¼ 0.68; duration: F(2,43)¼ 1.57, p¼ 0.22;
Figure 1c and d).
Overall, there was a significant effect of OXT in social
behaviors (frequency: F(2,43)¼ 3.10, po0.05; duration:
F(2,43)¼ 8.08, po0.005) and in nonsocial behaviors (fre-
quency: F(2,43)¼ 9.13, po0.0005; duration: F(2,43)¼ 7.95,
po0.005). In particular, post-hoc tests showed a decrease
in the frequency and duration of social behaviors in both
OXT 0.15 and 0.3 IU OXT-treated groups (po0.05) and an
increase in the frequency and duration of nonsocial
behaviors of both OXT-treated groups (po0.005;
Figure 1e and f) compared with VEH-treated mice.
During the male–female social interaction test, it is also
possible to record USVs emitted by the male mice that are
considered facets of social communication among rodents
(Scattoni et al, 2011). OXT treatment showed a signifi-
cant effect in the mean number of vocalizations emitted
(F(2,32)¼ 4.16, po0.05) and the duration of the USVs
(F(2,32)¼ 3.45, po0.05). In particular, the OXT 0.15-IU
group of mice showed a decrease in the number (po0.05)
and duration (po0.05; Supplementary Figure 2) of vocali-
zations emitted compared with the VEH group. There were
no differences in the peak frequencies (F(2,32)¼ 1.56,
p¼ 0.23) and amplitudes (F(2,32)¼ 1.54, p¼ 0.23; Figure 1g
and h, and Supplementary Figure 2) between the three
groups. Overall, these findings indicate that chronic
intranasal OXT treatment in normal C57BL/6J mice reduces
social interaction behaviors towards opposite-sex female
mice.
Chronic Intranasal OXT Treatment Decreased
Male–Male Social Interaction
To test whether chronic intranasal OXT treatment might
also impact same-sex social interactions, we used a novel,
automatic system algorithm which is able to precisely track
and simultaneously characterize social and nonsocial
behavioral interactions of multiple mice (Giancardo et al,
2013).
OXT treatment produced a significant effect in the
duration of body sniffing (F(2,23)¼ 4.90, po0.05) and
following (F(2,23)¼ 6.82, po0.005). Specifically, the OXT
0.3-IU group showed a decrease in the duration of body
sniffing (po0.05) and following (po0.05; Figure 2a) as
compared with the VEH group. There was also a decrease in
the duration of following behavior in the OXT 0.15 IU
relative to the VEH group (po0.005; Figure 2a). No
significant effects of OXT treatment were observed in the
duration of other social behaviors such as head sniffing
(F(2,23)¼ 1.01, p¼ 0.38), anogenital sniffing (F(2,23)¼ 1.70,
p¼ 0.21), and above (F(2,23)¼ 1.02, p¼ 0.38). On the other
hand, in nonsocial behaviors, a significant effect of OXT
treatment was observed in the duration of walking alone
(F(2,23)¼ 5.96, po0.05) and standing alone (F(2,23)¼ 3.35,
p¼ 0.05). Primarily, the OXT 0.15-IU group presented a
decrease in the duration of walking alone and standing
alone compared with the VEH group (po0.05; Figure 2b).
In summary, there was a significant OXT treatment effect
in the total duration of social behaviors (F(2,23)¼ 3.32,
p¼ 0.05; Figure 2c) while no significant treatment effect was
found in the total duration of nonsocial behaviors (F(2,23)¼
3.02, p¼ 0.07). Notably, the OXT 0.3-IU group presented a
decrease in the total duration of social behaviors (po0.05;
Figure 2c) in comparison with the VEH group. Overall, in
agreement with the male–female interaction test, these
findings strongly suggest that chronic intranasal OXT
treatment in normal C57BL/6J male mice reduces social
behavioral measures.
Chronic Intranasal OXT Treatment did not Affect Body
Weight, General Olfactory and Locomotor Abilities
In order to rule out possible confounding factors that might
have produced the social deficits found in OXT-chronically-
treated mice, we analyzed body weight, olfactory abilities
and gross locomotor activity following chronic intranasal
OXT treatment.
There was no significant effect of OXT treatment on body
weight (F(2,37)¼ 0.85, p¼ 0.44) and no significant effect of
treatment time interaction (F(6,111)¼ 1.62, p¼ 0.15). Thus,
chronic intranasal OXT treatment did not alter the body
weight of mice, up to 21 days of administration
(Supplementary Figure 3).
Olfactory abilities were tested by presenting the mice with
different nonsocial and social odors after the same OXT
intranasal treatment given in the social interaction tests. No
effect of chronic intranasal OXT treatment was detected
between the VEH- and OXT-treated groups (F(2,14)¼ 0.01,
p¼ 0.99), neither there was an effect of treatment odor
interaction (F(8,56)¼ 0.69, p¼ 0.70). There was an effect of
the odor stimulus (F(4,56)¼ 118.90, po0.0005) with the mice
spending more time sniffing the social odors as compared
with the nonsocial odors (po0.0005; Supplementary
Figure 4).
Gross locomotor functions were assessed in an empty
open-field arena. For the measure of total distance traveled,
there was an effect of treatment (F(2,43)¼ 3.77, po0.05),
an effect of time (F(11,473)¼ 47.35, po0.0005) and a
treatment time interaction (F(22,473)¼ 1.62, po0.05). In
particular, OXT 0.15 IU-treated mice showed slightly
reduced total distance traveled at time-points 20, 30, 55
Intranasal oxytocin in mice
H Huang et al
1106
Neuropsychopharmacology
and 60 min compared with VEH mice (po0.05;
Supplementary Figure 5). OXT 0.3 IU-treated mice showed
a slight decrease in distance traveled only at the 5-min time-
point relative to VEH mice (po0.05; Supplementary
Figure 5). All three groups of mice decreased the total
distance traveled over time (po0.0005), indicating normal
habituation to the novelty of the open-field arena. For the
measure of time spent being mobile, there was neither an
effect of treatment (F(2,43)¼ 0.21, p¼ 0.81), nor a
treatment time interaction (F(2,473)¼ 1.4, p¼ 0.11). All
three groups of mice showed a decrease in the time they
were mobile over the 1-hour test (F(11,473)¼ 23.42,
po0.0005; Supplementary Figure 5). For the measure of
time spent being immobile, no effect of treatment
(F(2,43)¼ 0.21, p¼ 0.81) or treatment time interaction
was observed (F(2,473)¼ 1.4, p¼ 0.11). All three groups of
mice showed an increase in the time they spent immobile
over the 1-hour test (F(11,473)¼ 23.41, po0.0005;
Supplementary Figure 5). Hence, these results indicate that
the social behavioral deficits found in C57BL/6J mice
chronically treated with intranasal OXT were not dependent
on alterations of body weight, olfactory abilities or gross
locomotor activity.
Chronic Intranasal OXT Treatment did not Alter
Temporal Order Object Recognition Memory Functions
OXT administration has been suggested to affect also
nonsocial recognition memory functions with generally
detrimental effects in healthy subjects and perhaps advan-
Figure 2 Chronic intranasal OXT treatment decreased male–male social interaction. (a) Duration of occurrence of various social behaviors such as head
sniffing, body sniffing, anogenital sniffing, going on top of another mouse (above) and following. (b) Duration of occurrence of various nonsocial behaviors
such as walking alone and standing alone. Sum of the duration of all events of above-mentioned (c) social behaviors and (d) nonsocial behaviors. Note that in
this experiment we used cagemates in order to avoid any possible aggressive behavior. Ns¼ 6 VEH, 16 OXT 0.15 IU/5 ml, 4 OXT 0.3 IU/5 ml. *po0.05,
**po0.005 vs VEH.
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tageous effects in schizophrenia (Feifel et al, 2012a;
Heinrichs et al, 2004; Herzmann et al, 2012). To evaluate
whether chronic intranasal OXT treatment might affect
recognition memory, we tested VEH- and OXT-intranasally-
treated mice in a temporal order object recognition task.
Lesion and disconnection studies in rodents (Barker et al,
2007; Barker and Warburton, 2011) have demonstrated that
memory functions measured in this task are critically
dependent on an integrated information flow between the
medial prefrontal cortex (mPFC), the perirhinal cortex
(PRH) and the hippocampus.
The performances of VEH-treated and OXT-treated mice
in this task were equal (F(2,41)¼ 0.14, p¼ 0.87; Supplemen-
tary Figure 6). Similar to VEH-treated mice, OXT 0.15-IU
and 0.3-IU groups showed positive discrimination between
the object presented least recently (from sample phase 1)
and the object presented most recently (from sample phase
2). These results suggest that chronic intranasal OXT
treatment did not alter object memory abilities that depend
on intact mPFC, hippocampus and PRH in wild-type
C57BL/6J mice.
Acoustic Startle and Prepulse Inhibition are Unaltered
by Chronic Intranasal OXT Treatment
Systemic subcutaneous injection of exogenous OXT might
affect startle responses and prepulse inhibition (PPI) of an
acoustic startle in rats (Feifel et al, 2012b). PPI is a measure
of inhibitory sensorimotor gating abilities with high
translational validity, as it can be studied in both mice
and humans, and is found to be attenuated in patients with
schizophrenia and autism spectrum disorders (Barker and
Warburton, 2011; Braff et al, 2001; Kumari et al, 2005;
Papaleo et al, 2008; Papaleo et al, 2012). Thus, we explored
the startle response and PPI in mice chronically treated with
intranasal VEH or OXT.
There was no effect of treatment in either acoustic startle
reactivity to the 120-dB stimulus or basal activity in the
apparatus when no stimulus was presented (F(2,77)¼ 0.69,
p¼ 0.50; Supplementary Figure 6). There was no effect of
interaction of treatment and acoustic startle reactivity
(F(2,77)¼ 0.77, p¼ 0.47). Similarly, analysis of PPI with a
120-dB acoustic startle stimulus showed no effect of
treatment (F(2,77)¼ 0.07, p¼ 0.93) or treatment PPI inter-
action (F(8,308)¼ 0.78, p¼ 0.62; Supplementary Figure 6).
These results indicate that chronic intranasal OXT treat-
ment did not alter reactivity to stressful events or
sensorimotor gating abilities in healthy C57BL/6J mice.
Chronic Intranasal OXT Treatment Decreased OXT
Receptors in the Brain
Upon agonist stimulation, OXT receptors (OXTRs) can
undergo desensitisation and internalization (Conti et al,
2009). To evaluate whether chronic intranasal OXT treat-
ment might affect the number of OXTRs in the brains of
mice, we then quantified them using an autoradiography
binding assay. As the functionally related vasopressin V1a
receptor (V1aR) can be potentially up-/downregulated
following OXT treatment, we also quantified V1aR expres-
sion by autoradiography.
Figure 3 Chronic intranasal OXT treatment decreased OXT receptors in various brain areas. Representative autoradiographs showing the rostro-caudal
ligand binding (a) of 20 pmol/l I125-labeled OVTA, a potent and selective ligand for OXTR and (b) of 20 pmol/l I125-labeled linear vasopressin antagonist
(LVA), a potent and selective ligand for V1aR. Autoradiograms were obtained from coronal sections of 3-month-old brains of mice chronically treated with
intranasal OXT 0.15 IU/5 ml (OXT 0.15), OXT 0.3 IU/5 ml (OXT 0.3) or vehicle (VEH). (c and d) Quantification of the autoradiographic I125 receptors was
obtained using NIH ImageJ- Software. Data is expressed as nCi/mg tissue equivalent. Amy, amygdala; AON, anterior olfactory nucleus; Hippo, hippocampus;
LS, lateral septum; NAcc, nucleus accumbens; PIR, piriform cortex; VP, ventral pallidum. Ns¼ 7 for each group; *po0.05; **po0.005; ***po0.0005
vs VEH.
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As shown in Figure 3, mice treated with OXT had a
significant decrease in OXTR-binding sites in all of the
regions considered. The higher dose, OXT 0.30 IU, caused a
significantly (po0.005) greater reduction in OXTR binding
than the lower OXT 0.15 IU dose in the lateral septum ( 25
vs  9%), anterior olfactory nucleus ( 21 vs  9%) and
amygdala ( 18 vs  8%); whereas the two doses had
comparable effects in hippocampus ( 10 vs  9%),
piriform cortex ( 15 vs  17%) and nucleus accumbens
( 17 vs  15%).
Interestingly, we observed that chronic intranasal OXT
treatment increased the V1aR-binding sites in the lateral
septum, that is, þ 18% in OXT 0.15 IU-treated mice and
þ 31% in OXT 0.3 IU-treated mice (Figure 3b). In contrast,
there was no effect of the OXT treatment on V1aR-binding
sites in all the other regions considered, including
hippocampus, anterior olfactory nucleus, piriform cortex,
ventral pallidum and amygdala.
These results clearly show that chronic intranasal OXT
treatment reduced OXTRs throughout the brain whereas
having much less impact on V1aR vasopressin receptors.
Acute Intranasal OXT Treatment Increased
Male–Female Social Interaction
Chronic intranasal OXT selectively altered social behavioral
measures. To investigate whether a single acute intranasal
administration of OXT would have different effects as
chronic treatments, we intranasally administered VEH, OXT
0.15 IU or OXT 0.3 IU to male mice, just 5 min before
performing the same social interaction tests as performed
after chronic intranasal OXT.
There was a significant effect of OXT treatment in the
frequency of anogenital sniffing events (F(2,14)¼ 8.05,
po0.005). Male mice treated with a single administration
of 0.15 and 0.3 IU OXT before the test showed increases in
the frequency of anogenital sniffing events as compared
with the VEH group (po0.05; Figure 4a). The number of
body-sniffing events display a trend of OXT-dependent
dose-response increase (F(2,14)¼ 8.05, p¼ 0.09; Figure 4a).
No significant effect of OXT treatment was observed in the
frequency of other measures of social interaction such as
head sniffing (F(2,14)¼ 0.12, p¼ 0.89) and following
(F(2,14)¼ 0.92, p¼ 0.42; Figure 4a). Similarly, there was no
significant effect of OXT treatment in the duration of social
behaviors, such as head sniffing (F(2,14)¼ 0.09, p¼ 0.91),
body sniffing (F(2,14)¼ 1.34, p¼ 0.29), anogenital sniffing
(F(2,14)¼ 0.56, p¼ 0.58) and following events (F(2,14)¼ 2.62,
p¼ 0.11; Figure 4b). Both OXT 0.15 and 0.3 IU groups
showed no significant differences in the frequency and
duration of all nonsocial behaviors including standing/
walking alone (frequency: F(2,14)¼ 0.65, p¼ 0.54; duration:
F(2,14)¼ 0.51, p¼ 0.61), digging (frequency: F(2,14)¼ 1.24,
p¼ 0.32; duration: F(2,14)¼ 1.24, p¼ 0.32), grooming
(frequency: F(2,14)¼ 0.51, p¼ 0.61; duration: F(2,14)¼ 0.20,
p¼ 0.82), rearing (frequency: F(2,14)¼ 2.35, p¼ 0.13; dura-
tion: F(2,14)¼ 1.34, p¼ 0.29), wall rearing (frequency:
F(2,14)¼ 1.98, p¼ 0.17; duration: F(2,14)¼ 1.12, p¼ 0.35), in
comparison with the VEH group (Figure 4c and d).
Overall, there was a significant OXT treatment effect in
the frequency of total social behaviors (F(2,14)¼ 4.09,
po0.05) but no treatment-dependent differences in the
frequency of total nonsocial behaviors (F(2,14)¼ 0.69,
p¼ 0.52). The OXT 0.3-IU group showed increased total
social behaviors compared with the VEH group (po0.05;
Figure 4e).
No significant difference was observed in the duration
(F(2,14)¼ 2.25, p¼ 0.14), mean number (F(2,14)¼ 0.67,
p¼ 0.53), peak frequencies (F(2,14)¼ 0.42, p¼ 0.67) and
amplitudes (F(2,14)¼ 0.36, p¼ 0.70) of the USVs emitted by
the OXT-treated groups compared with the VEH group
(Figure 4g and h and Supplementary Figure 7).
Overall, these findings indicate that, in contrast to chronic
treatments, acute intranasal OXT administration in normal
C57BL/6J mice increases social interaction behaviors
towards opposite-sex female mice.
Acute Intranasal OXT Treatment did not Affect Social
Interaction between Familiar Males
To check if acute intranasal OXT treatment might also
impact same-sex social interactions, 5 min after a single
intranasal administration of VEH, OXT 0.15 IU or OXT
0.3 IU, male mice were evaluated for interactions with their
cagemates in an open-field arena as done after chronic
intranasal OXT (Figure 5).
No significant effects of acute intranasal OXT adminis-
tration were evident in any of the measures of social
behaviors between the male–male cagemates, such as head
sniffing (F(2,15)¼ 0.60, p¼ 0.56), body sniffing (F(2,15)¼ 1.68,
p¼ 0.22), anogenital sniffing (F(2,15)¼ 0.94, p¼ 0.41) going
on top of another mouse—‘above’ (F(2,15)¼ 2.31, p¼ 0.13)
and following (F(2,15)¼ 0.57, p¼ 0.58). Similarly, there were
no significant effects of a single intranasal OXT adminis-
tration in any of the nonsocial behavior measures, namely,
standing alone (F(2,15)¼ 0.46, p¼ 0.64) and walking alone
(F(2,15)¼ 0.31, p¼ 0.74). Thus, in contrast to the chronic
treatments, acute intranasal OXT produced no major social
interaction changes between male–male familiar cagemates.
Acute Intranasal OXT Treatment Reduced Social
Interaction between Unfamiliar Males
To test if the lack of effects in the previous male–male social
interaction test following acute intranasal OXT might have
been dependent on the familiarity of the social stimulus,
5 min after a single intranasal administration of VEH, OXT
0.15 IU or OXT 0.3 IU, male mice were evaluated in a
habituation/dishabituation social memory test.
A significant OXT treatment  trial interaction effect was
evident for the duration of social (F(6,111)¼ 3.49, p¼ 0.003;
Figure 5e) and nonsocial behaviors (F(6,111)¼ 2.95, p¼ 0.01;
Figure 5f). As expected, VEH-treated mice showed a
characteristic decline (po0.01) in the time spent investigat-
ing the same stimulus male, with a full recovery following
the introduction of a new unfamiliar male (po0.001). In
contrast, both OXT 0.15- and 0.3 IU-treated groups showed
no changes (p’s40.80) in the exploration of unfamiliar
males. Almost no aggressive/fighting behaviors were
observed (ie, VEH group: 1 mouse out of 13; OXT 0.15-IU
group: 1 out of 14; OXT 0.3-IU group: 1 out of 13) with no
OXT treatment (F(2,37)¼ 1.14, p¼ 0.33) or OXT treatment
trial interaction effects (F(6,111)¼ 1.15, p¼ 0.34). Thus, in
agreement with the previous experiment, acute intranasal
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Figure 4 Acute intranasal OXT treatment increased male–female social interaction. (a) Frequency of occurrence of various social behaviors such as head
sniffing, body sniffing, angogenital sniffing and following in male mice towards female stimulus mice after a single acute dose of saline (VEH), OXT 0.15 IU/5 ml
or 0.3 IU/5 ml. (b) Duration of events of above-mentioned social behaviors. (c) Frequency of occurrence of various nonsocial behaviors such as standing/
walking alone, digging, grooming, rearing and wall rearing. (d) Duration of events of above-mentioned nonsocial behaviors. (e) Frequency of all events of
social and nonsocial behaviors. (f) Duration of all events of social and nonsocial behaviors. (g) Mean number of USV calls per minute, and (h) mean duration
of USVs in milliseconds. Ns¼ 6 acute VEH, 6 acute OXT 0.15 IU/5 ml, 6 acute OXT 0.3 IU/5 ml. *po0.05, **po0.005 vs VEH.
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OXT treatment did not alter social exploration of a familiar
male whereas; in contrast, it reduced exploration of an
unfamiliar male.
DISCUSSION
The main finding of the present study was that, in wild-type
C57BL/6J mice, chronic and acute intranasal OXT produced
selective but divergent effects in social behavior. In
particular, chronic intranasal OXT treatment produced a
selective reduction of social behaviors indiscriminately
towards same or opposite sex and towards familiar or
unfamiliar subjects. Chronic intranasal OXT concomitantly
produced a reduction of OXT receptors throughout
the brain. Conversely, acute intranasal OXT treatment
increased social behaviors towards opposite-sex novel-
stimulus females, did not alter social interactions in same-
sex familiar males, and reduced social behaviors towards
same-sex novel-stimulus male mice. Finally, prolonged
exposure to intranasal OXT treatments did not alter, in
wild-type animals, neither parameters of general health,
such as body weight, gross locomotor activity, olfactory and
auditory functions, nor parameters of memory and
sensorimotor gating abilities.
C57BL/6J male mice chronically treated with intranasal
OXT decreased social interaction behaviors towards oppo-
site-sex novel-stimulus female mice as well as towards
same-sex familiar cagemates. Concomitantly, chronic in-
tranasal OXT treatment decreased the number of USVs,
revealing that this treatment consistently reduced both
social behaviors and communication. Intranasal OXT
Figure 5 Acute intranasal OXT treatment did not alter social interaction between familiar males but reduced it between unfamiliar males. (a) Duration of
occurrence of various social behaviors such as nose-to-body, nose-to-nose, nose-to-back sniffing, going on top of another mouse—‘above’ and following in
male mice towards male cagemates after a single acute dose of saline (VEH), OXT 0.15 IU/5 ml or 0.3 IU/5 ml. (b) Duration of occurrence of various nonsocial
behaviors such as walking alone and standing alone. Sum of the duration of all events of the above-mentioned (c) social and (d) nonsocial behaviors. Ns¼ 6
acute VEH, 6 acute OXT 0.3 IU/5 ml, 6 acute OXT 0.15 IU/5 ml. (e and f) Data depict the amount of time in seconds allocated to (e) investigation of the same
unfamiliar male and (f) other nonsocial behaviors in the cage but not towards the stimulus mouse during each of three successive 1-min trials. A fourth
‘dishabituation’ trial depicts the response of the subject males to the presentation of a new unfamiliar male in a 1-min pairing 3min after the third trial.
Ns¼ 13 acute VEH, 14 acute OXT 0.15 IU/5 ml, 13 acute OXT 0.3 IU/5 ml. *po0.05 vs trials 2 and 3.
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administration in healthy humans have also indicated
OXT’s modulation of psychosocial functions, such as
reducing endocrinal and behavioral responses to social
stress, enhancing stress-buffering effects of social support
(Heinrichs et al, 2003), attenuating activation of amygdala
to social stimuli (Baumgartner et al, 2008; Domes et al,
2007a; Gamer et al, 2010; Kirsch et al, 2005), improving
social and emotion recognition (Domes et al, 2007b;
Guastella et al, 2008; Rimmele et al, 2009), attachment
(Buchheim et al, 2009) and heterosexual couples interaction
(Ditzen et al, 2009). Despite this, there is a lack of
information on long-term effects of intranasal OXT in
healthy subjects; as only recently, one study has started to
investigate the effects of chronic intranasal OXT adminis-
tration in prairie voles (Bales et al, 2012). Thus, a possible
reason for the apparent discrepancies between our findings
and current evidence from human studies regarding OXT-
induced effects in social-related behaviors might be that a
prolonged over-stimulation of a ‘healthy’ oxytocinergic
system, with no inherent deficits in social interaction and
normal endogenous levels of OXT, might result in detri-
mental effects. Indeed, human studies have prevalently
used acute administration of OXT in healthy subjects
(Baumgartner et al, 2008; Buchheim et al, 2009; Ditzen et al,
2009; Domes et al, 2007a; Domes et al, 2007b; Gamer et al,
2010; Guastella et al, 2010; Heinrichs et al, 2003; Kirsch
et al, 2005; MacDonald et al, 2011; Rimmele et al, 2009),
whereas prolonged OXT treatments have been adopted only
in pathological states presenting social deficits (Feifel et al,
2012a; Feifel et al, 2010; Tachibana et al, 2013). Thus,
intranasal administration of OXT might act to increase the
concentration of OXT beyond endogenous levels in a
normal-functioning brain resulting in desensitisation and
hence, down-regulation of OXTRs. Indeed, the oxytocin
receptor is a G protein-coupled receptor and can undergo
desensitisation and internalization after agonist application
(Conti et al, 2009; Insel et al, 1992). Accordingly, we have
shown that chronic intranasal OXT treatment reduced the
number of OXTRs in various brain regions, namely: lateral
septum, hippocampus, piriform cortex, anterior olfactory
nucleus, nucleus accumbens and amygdala.
The brain areas in which we found alterations of OXT
receptors are involved in the regulation of social recogni-
tion. In particular, the amygdala is the site of convergence
of socially-relevant olfactory inputs from the main and
accessory olfactory systems; the anterior olfactory nucleus
and the piriform cortex exert a key role in integrating
olfactory information (Choleris et al, 2009); the lateral
septum, hippocampus and ventral pallidum are areas where
the forebrain OXTR knockout mice that present social
recognition impairments, showed reduced OXTR expres-
sion (Lee et al, 2008; Macbeth et al, 2009). Furthermore,
chronic intranasal OXT treatment increased V1aR-binding
sites in the lateral septum, a key area for V1aR-mediated
regulation of social recognition (Bielsky and Young, 2004;
Landgraf et al, 1995). These evidence correlate with the
reduction of social behaviors following chronic intranasal
OXT treatment, and suggest that intranasal OXT treatments
effectively influence and modulate the brain’s oxytocinergic
and vasopressinergic systems. The significance of these
brain modulations and the underlying neurobiological
mechanisms represents an important subject for future
study. However, these findings corroborate the hypothesis
that a prolonged over-stimulation of a ‘healthy’ oxytociner-
gic system might result in detrimental effects, at least in
social behavior.
In contrast to the indiscriminate decrease in social
behaviors following chronic intranasal OXT, a single acute
intranasal dose of OXT in normal C57BL/6J male mice
modulated social behaviors differently, depending on the
sex (opposite- vs same-sex), and on the different social
value (novel vs familiar) of the interacting mouse. In
particular, acute intranasal OXT increased social behaviors
towards a novel female stimulus mouse did not change
social interaction between male–male familiar cagemates,
but reduced social behaviors towards a novel unfamiliar
male mouse. A wealth of evidence indicates that behavioral
and histological measures in both the OXT system and
OXT-mediated effects are sex-dependent (Macdonald,
2012). Although our experimental setting was not specifi-
cally designed to investigate sexual behaviors but that of a
male’s approach towards a sexually-receptive female, our
results agree with previous works showing that either
intraperitoneally or intracerebroventricularly acutely-in-
jected OXT facilitate reproductive and sociosexual beha-
viors in male rodents (Arletti et al, 1985; Neumann, 2008;
Witt, 1995). Moreover, intranasal OXT might be involved in
the stress-protective and health-promoting role of positive
heterosexual couples interactions (Ditzen et al, 2009).
Furthermore, in agreement with our results showing
selective reduced social behaviors towards a novel unfami-
liar male subject following acute OXT, an acute intracer-
ebroventricular injection of OXT in wild-type male mice
reduced the sociability towards a stranger male subject (Sala
et al, 2011). Similarly, our data agree with and might also
explain recent findings showing that acute OXT aerosol in
male monkeys reduced social vigilance for unfamiliar
dominant faces (Ebitz et al, 2013). Altogether, our results
show that the OXT intranasal route of administration in
mice might be a valuable tool to preclinically test novel
compounds and to better investigate the neural mechanisms
of OXT-mediated behaviors in different social settings (eg,
differentiating between novel vs familiar and opposite- vs
same-sex social interactions).
In conclusion, we demonstrated that intranasal OXT
treatment in normal C57BL/6J mice can reliably modulate
the oxytocinergic system to selectively alter social behavior;
most importantly, different effects on specific social
behaviors are obtained upon chronic or acute intranasal
administration. These preclinical findings constitute a starting
point in unraveling the mechanistic impact of intranasal
OXT. Moreover, the feasibility of administering OXT
intranasally in mice pave the way towards the development
of more selective and personalized use of OXT intranasal
treatments based on genetic and pharmacological screen-
ings. These bear important clinical implications for the
life-long management of intranasal OXT treatments to be
applied to the human population.
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